Purpose This study aimed to investigate the clinical factors associated with breast cancer (BRCA) dural metastases (DMs), their impact on prognosis compared to brain parenchymal metastases (BPMs) alone, and differences between DM subtypes, aiming to inform clinical decisions.
Materials and Methods We retrospectively analyzed 119 patients with BRCA with brain metastasis, including 91 patients with BPM alone and 28 patients with DM. Univariate and multivariate analyses were performed to compare the clinical characteristics between the two groups and within subtypes of DM. Overall survival after DM (OSDM) and the interval from DM to leptomeningeal carcinomatosis (LMC) were compared using Kaplan-Meier analysis.
Results DM was notably linked with extracranial metastasis, luminal-like BRCA subtype (p=0.033), and skull metastases (p < 0.001). Multiple logistic regression revealed a strong association of DM with extracranial and skull metastases, but not with subtype or hormone receptor status. Patients with DM did not show survival differences compared with patients with BPM alone. In the subgroup analysis, nodular-type DM correlated with human epidermal growth factor receptor 2 status (p=0.044), whereas diffuse-type DM was significantly associated with a higher prevalence of the luminal-like subtype (p=0.048) and the presence of skull metastasis (p=0.002). Patients with diffuse DM did not exhibit a significant difference in OSDM but had a notably shorter interval from DM to LMC compared to those with nodular DM (p=0.049).
Conclusion While the impact of DM on the overall prognosis of patients with BRCA is minimal, our findings underscore distinct characteristics and prognostic outcomes within DM subgroups.
Citations
Citations to this article as recorded by
Small-cell neuroendocrine carcinoma of the cervix with leptomeningeal spread: A rare coincidence report and literature review Mohammed A. Azab, Oday Atallah, Nour El-Gohary, Ahmed Hazim, Hamed Abdelma’aboud Mostafa Surgical Neurology International.2024; 15: 310. CrossRef
Left homonymous hemianopia as an atypical manifestation of isolated pachymeningeal metastasis secondary to breast cancer: Case report and review of the literature Aziz Ahizoune, Moad Belouad, Houda Alloussi, Mohamed Allaoui, Mohamed Hamid, Ahmed Bourazza Radiology Case Reports.2024; 19(11): 5459. CrossRef
Purpose For liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1).
Materials and Methods We reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS.
Results The median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes.
Conclusion Clinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment.
Citations
Citations to this article as recorded by
Recurrent Intrathoracic Liposarcoma: A Case Report and a Comprehensive Literature Review of a Rare Clinical Entity Vasileios Leivaditis , Manfred Dahm , Athanasios Papatriantafyllou, Hans-Georg Keul, Lydia Kohl, Hans-Joachim Schäfers Cureus.2024;[Epub] CrossRef
Clinicopathological Features of Intrathoracic Liposarcoma—A Systematic Review with an Illustrative Case Kajetan Kiełbowski, Nikola Ruszel, Seweryn Adam Skrzyniarz, Małgorzata Edyta Wojtyś, Rafał Becht, Konrad Ptaszyński, Darko Gajić, Janusz Wójcik Journal of Clinical Medicine.2022; 11(24): 7353. CrossRef
Purpose
The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.
Materials and Methods
Medical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed.
Results
Five hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%. The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis (≥ stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001).
Conclusion
In East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia.
Citations
Citations to this article as recorded by
Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya Perez K. Olewe, Shehu Shagari Awandu, Elly O. Munde, Samuel B. Anyona, Evans Raballah, Asito S. Amolo, Sidney Ogola, Erick Ndenga, Clinton O. Onyango, Rosemary Rochford, Douglas J. Perkins, Collins Ouma BMC Cancer.2023;[Epub] CrossRef
iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma Runhong Yu, Linna Cheng, Shiwei Yang, Yufeng Liu, Zunmin Zhu Frontiers in Oncology.2022;[Epub] CrossRef
Joon Young Hur, Youjin Kim, Ghee-Young Kwon, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Su Jin Lee, Se Hoon Park
Cancer Res Treat. 2019;51(4):1269-1274. Published online January 9, 2019
Purpose
Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who failed platinum-based chemotherapy.
Materials and Methods
A retrospective study using the Samsung Medical Center cancer chemotherapy registry was performed on 50 consecutive patients with mUC treated with atezolizumab, regardless of their PD-L1(SP142) status, as salvage therapy after chemotherapy failure between May 2017 and June 2018. Endpoints included overall response rate (RR), progression-free survival (PFS), and safety.
Results
Among 50 patients, men constituted 76% and the median age was 68 years (range, 46 to 82 years). Twenty-three patients (46%) received atezolizumab as second-line therapy. PD-L1 (SP142) status IC0/1 and IC2/3 were found in 21 (42%) and 21 (42%) of patients, respectively; in eight patients (16%), PD-L1 (SP142) expression was not available. Atezolizumab was generally well tolerated, with pruritus and fatigue being the most commonly observed toxicities. As a result, partial response was noted in 20 patients (40%), with 12 (24%) stable diseases. RRwas higherin IC2/3 (62%) than in IC0/1 patients (24%, p=0.013). The median PFS was 7.4 months (95% confidence interval, 3.4 to 11.4 months). As expected, PFS also was significantly longer in IC2/3 patients than in IC0/1 (median, 12.7 vs. 2.1 months; p=0.005). PFS was not significantly influenced by age, sex, performance status, number of previous chemotherapy, site of metastases, or any of the baseline laboratory parameters.
Conclusion
In this retrospective study, atezolizumab demonstrated clinically efficacy and tolerability in unselected mUC patients who failed platinum-based chemotherapy.
Citations
Citations to this article as recorded by
Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer Rocío Díaz Acedo, Mercedes Galvan Banqueri, Silvia Artacho Criado, Eva María Fernández Parra, Rocío Jiménez Galán, Ana Isabel Gago Sánchez, Juan Francisco Marín Pozo, María José Martínez Bautista International Journal of Clinical Pharmacy.2024; 46(2): 382. CrossRef
Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park Biomedicines.2022; 10(8): 2005. CrossRef
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options Inkeun Park, Jae Lyun Lee The Korean Journal of Internal Medicine.2020; 35(4): 834. CrossRef
Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim
Cancer Res Treat. 2018;50(1):175-182. Published online March 30, 2017
Purpose
This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence.
Materials and Methods
A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients.
Results
A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes.
Conclusion
GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.
Citations
Citations to this article as recorded by
Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma Shuang Liang, Lanting Ji, Zhenyuan Yu, YaHsin Cheng, Ruifang Gao, Wenpeng Yan, Fang Zhang Hereditas.2024;[Epub] CrossRef
Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives Tae Hun Kim, Ki Hyuk Sung, So Hak Chung Journal of the Korean Orthopaedic Association.2024; 59(1): 22. CrossRef
Leiomyosarcoma of stomach extending to gastroesophageal junction and distal esophagus as a rare cause of dysphagia -A case report Lilamani Rajthala, Sagar Gyawali, Sabin Banmala, Surendra Shah Annals of Medicine & Surgery.2024;[Epub] CrossRef
Real‐World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center Isabella Wilson, Madeleine Strach, Vivek Bhadri, Michelle Harrison, Whiter Tang, Peter Grimison Asia-Pacific Journal of Clinical Oncology.2024;[Epub] CrossRef
Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma Prapassorn Thirasastr, Heather Lin, Behrang Amini, Wei‐Lien Wang, Jeffrey M. Cloutier, Elise F. Nassif, Emily Z. Keung, Christina L. Roland, Barry Feig, Dejka Araujo, Robert S. Benjamin, Anthony P. Conley, John A. Livingston, Joseph Ludwig, Shreyaskumar P Cancer Medicine.2023; 12(4): 4282. CrossRef
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time Tuyen Duong Thanh Nguyen, Yan Wang, Tuyen N. Bui, Rossana Lazcano, Davis R. Ingram, Min Yi, Varshini Vakulabharanam, Linjie Luo, Marc A. Pina, Cansu Karakas, Mi Li, Nicole M. Kettner, Neeta Somaiah, Peter J. Hougton, Osama Mawlawi, Alexander J. Lazar, Kel Cancer Research.2023; 83(6): 939. CrossRef
A competing risk-based nomogram to predict cancer-specific survival in patients with retroperitoneal leiomyosarcoma Qian Fang, Guojing Cai, Guizeng Chen, Xiang Xu, Haifeng Zeng, Yulong He, Shirong Cai, Hui Wu Heliyon.2023; 9(6): e16867. CrossRef
Chemotherapeutic drugs for soft tissue sarcomas: a review Zhichao Tian, Weitao Yao Frontiers in Pharmacology.2023;[Epub] CrossRef
Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma Szu-Yun Niu, Lou Sun, Shih-Tien Hsu, Sheau-Feng Hwang, Chih-Ku Liu, Yu-Hsiang Shih, Ting-Fang Lu, Yen-Fu Chen, Li-Ching Lai, Pei-Lun Chang, Chien-Hsing Lu Frontiers in Oncology.2023;[Epub] CrossRef
Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature Siran Yang, Wenqing Wang, Nan Bi, Zongmei Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang, Luhua Wang Medicine.2022; 101(42): e31215. CrossRef
Synovial sarcoma in children: A 15-YEAR experience at a tertiary pediatric center in Argentina E. Rossetti, G. Gonzalez Diaz, J. Lopez Marti, S. Innocenti, W. Cacciavillano, G. Felizzia, M. Viso, M.L. Ramos, P. Zubizarreta, A. Rose Pediatric Hematology Oncology Journal.2021; 6(4): 175. CrossRef
Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas Dennis Christoph Harrer, Sebastian Buschauer, Ulrich Sterz, Karin Menhart, Christina Wendl, Daniel Heudobler, Matthias Grube, Tobias Pukrop, Wolfgang Herr, Martin Vogelhuber Frontiers in Oncology.2021;[Epub] CrossRef
Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice Waleed A. Q. Hailan, Faisal M. Abou-Tarboush, Khalid M. Al-Anazi, Areeba Ahmad, Ahmed Qasem, Mohammad Abul Farah Drug and Chemical Toxicology.2020; 43(2): 158. CrossRef
Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim Translational Oncology.2019; 12(2): 269. CrossRef
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi Laboratory Investigation.2019; 99(9): 1309. CrossRef
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Norihiko Sugisawa, Jun Ho Park, Sahar Razmjooei, Yuki Katsuya, Maryam Barangi, Yunfeng Li, Scott D. Nelson, Takashi Murakami, Yuki Homma, Yukihiko Hiroshima, Ryusei Matsuyama, Michael Bouve Biomedicine & Pharmacotherapy.2019; 117: 109093. CrossRef
Adipogenesis induces growth inhibition of dedifferentiated liposarcoma Yu Jin Kim, Dan Bi Yu, Mingi Kim, Yoon‐La Choi Cancer Science.2019; 110(8): 2676. CrossRef
Leiomyosarcoma of the Stomach with Metastasis to the Liver: A Case Report With Review of the Literature Varshil Mehta, Monali Rajawat, Sameer Rastogi, Ravi H Phulware, Roman Mezencev Future Science OA.2018;[Epub] CrossRef
Systemic treatment in adult uterine sarcomas I.M.E. Desar, P.B. Ottevanger, C. Benson, W.T.A. van der Graaf Critical Reviews in Oncology/Hematology.2018; 122: 10. CrossRef
Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature Tomoko Yoshimoto, Shinichiro Kobayashi, Kengo Kanetaka, Kazuma Kobayashi, Yasuhiro Nagata, Michi Morita, Yuriko Isagawa, Naoe Kinoshita, Mitsuhisa Takatsuki, Susumu Eguchi Surgical Case Reports.2018;[Epub] CrossRef